NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Sapu Nano's First In-Human Clinical Trial of Sapu-003 Intravenous Everolimus
TL;DR
Sapu Nano's Sapu-003 offers a competitive edge with higher bioavailability and better efficacy than oral Everolimus for breast cancer treatment.
Sapu-003 is an injectable formulation of Everolimus developed through partnerships with SOCRU, Ingenū, and Medicilon to enhance drug delivery.
This clinical trial advances breast cancer treatment by potentially providing more effective therapy options for patients worldwide.
Sapu Nano unveiled its first human clinical trial of intravenous Everolimus at the Australian Translational Breast Cancer Research Symposium.
Found this article helpful?
Share it with your network and spread the knowledge!
Sapu-003 is an injectable formulation of Everolimus (Afinitor®) that is being developed as an intravenous treatment, with the trial focused on breast cancer applications.
This represents Sapu Nano's first in-human clinical trial and features an intravenous formulation that aims to offer higher bioavailability and better efficacy than oral versions of Everolimus.
The trial was revealed at the Australian Translational Breast Cancer Research Symposium (ATBCR).
The trial is being conducted alongside partners including the Southern Oncology Clinical Research Unit (SOCRU), Ingenū, and Medicilon.
Sapu Nano is part of the Sapu family of companies, which was established through GMP Biotechnology Limited, a joint venture between Oncotelic Therapeutics, Inc. (OTCQB: OTLC) and Dragon Overseas Capital Limited.
The intravenous formulation aims to provide higher bioavailability and better efficacy than oral versions of the drug Everolimus (Afinitor®).
The latest news and updates relating to OTLC are available in the company's newsroom at ibn.fm/OTLC.
BioMedWire published this announcement, which is a specialized communications platform focusing on biotechnology and biomedical sciences that provides wire solutions, press release enhancement, and social media distribution through the Investor Brand Network.
Curated from InvestorBrandNetwork (IBN)
